Compare Global X Robo Global Robotics & Automation ETF (ROBO) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robo Global Robotics & Automation ETF vs Tango Therapeutics Inc. — how do they compare? Global X Robo Global Robotics & Automation ETF trades at $76 (market cap $2.02B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Global X Robo Global Robotics & Automation ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Robo Global Robotics & Automation ETF for 38 Days and Tango Therapeutics Inc. for 0 Days on average.
| ROBO | TNGX | |
|---|---|---|
Market Cap | $2.02B | $3.75B |
Volume | 103,334 | 9,619,106 |
Sector | Sector/Thematic | Health |
52-Week High | $90.34 | $32.90 |
52-Week Low | $63.04 | $7.50 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ROBO Global Robotics and Automation Index ETF (ROBO) trades at $79.85, down 0.22% on the day, with technical indicators showing a bearish trend as moving averages signal selling pressure. The robotics ETF faces mixed sentiment amid AI-driven sector growth but lacks current fundamental data for valuation metrics. Recent news highlights robotics adoption expanding beyond automotive into manufacturing, healthcare, and military applications, though earnings visibility remains limited for underlying holdings.
The outlook for ROBO hinges on broader AI and robotics adoption trends, with potential from labor shortages and military demand, but risks include valuation concerns in tech and cyclical exposure. Investors should monitor earnings from constituent companies for fundamental validation of growth narratives amid neutral oscillator signals and bearish technical momentum.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
